Clinical Focus

  • Inflammatory Bowel Diseases
  • Gastroenterology

Academic Appointments

Administrative Appointments

  • Clinical Director, Inflammatory Bowel Disease Program, Division of Gastroenterology (2008 - Present)

Honors & Awards

  • Member, Alpha Omega Alpha Honor Medical Society (2000)
  • Intern of the Year, Charity Hospital, New Orleans (2001)
  • Intern, Teaching Excellence Award (2001)
  • Resident, Teaching Award (2004)
  • Faculty, Stanford GI Fellows Teaching Award (2014)

Boards, Advisory Committees, Professional Organizations

  • Member, American Gastroenterology Association (2006 - Present)
  • Member, American College of Gastroenterology (2004 - Present)
  • Member, Crohn's and Colitis Foundation of America (CCFA) (2006 - Present)
  • Co-Chair, CCFA Northern California Chapter: Community Medical Advisory Committee (2012 - 2014)
  • Member, CCFA Northern California Chapter: Community Medical Advisory Committee (2008 - Present)
  • Member, Woman Educators Clinicians and Researchers in IBD (WE CARE) (2006 - Present)

Professional Education

  • Residency:Louisiana State University - New Orleans (2003) LA
  • Fellowship:University of Chicago Hospitals and Health System (2008) IL
  • Advanced Fellowship, University of Chicago, Inflammatory Bowel Disease (2008)
  • Board Certification: Gastroenterology, American Board of Internal Medicine (2007)
  • Fellowship:Ochsner Foundation Hospital (2007) LA
  • Residency, LSU Health Sciences Center, Chief Resident (2004)
  • Residency, LSU Health Sciences Center, Internal Medicine (2003)
  • Medical Education:Louisiana State University - New Orleans (2000) LA

Research & Scholarship

Current Research and Scholarly Interests

I joined Stanford in 2008 after specialized training in Crohn's disease and ulcerative colitis at the University of Chicago. I am the Clinical Director of the Inflammatory Bowel Disease Program (IBD). My clinical and research interests within IBD include the application of novel treatments within IBD, the study of IBD-associated conditions and cancer evaluation and prevention.

Clinical Trials

  • Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls Not Recruiting

    This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.

    Stanford is currently not accepting patients for this trial. For more information, please contact Shamita Shah, MD, 650-736-0431.

    View full details

  • Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis Recruiting

    The purpose of this study is to evaluate the safety and effectiveness of trichuris suis ova (TSO) in ulcerative colitis (UC). We will look at how TSO affects the body's immune response and if there are related changes in participants' UC.

    View full details

  • Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Not Recruiting

    Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.

    Stanford is currently not accepting patients for this trial. For more information, please contact Ken Cox, MD, 650-721-2250.

    View full details


2014-15 Courses

Graduate and Fellowship Programs


All Publications

  • Fecal DNA Testing for Colorectal Neoplasia in IBD: Could it be as Simple as a Stool Study? Gastroenterology Quan, S. Y., Shah, S. B. 2013; 145 (2): 479-481

    View details for DOI 10.1053/j.gastro.2013.06.018

    View details for PubMedID 23791792

  • Enhanced imaging technologies in detecting dysplasia in IBD: narrowing or widening our options? Gastroenterology Sinha, S. R., Shah, S. B. 2012; 143 (4): 1108-1110

    View details for DOI 10.1053/j.gastro.2012.08.019

    View details for PubMedID 22917863

  • Fast routes to new therapies: what do epilepsy and inflammatory bowel disease have in common? Gastroenterology Nimgaonkar, A., Shah, S. B. 2012; 142 (3): 670-671

    View details for DOI 10.1053/j.gastro.2012.01.018

    View details for PubMedID 22281276

  • Plant extract: a natural immune booster for ulcerative colitis. Gastroenterology Shah, S. B. 2011; 141 (4): 1525-1526

    View details for DOI 10.1053/j.gastro.2011.08.017

    View details for PubMedID 21871453

  • Stretching the limits in Crohn's disease. Gastroenterology Shah, S. B. 2011; 140 (3): 1099-1101

    View details for DOI 10.1053/j.gastro.2011.01.009

    View details for PubMedID 21276767

  • Capsule Endoscopy in the Diagnosis of Suspected Small Bowel Involvement with Crohn's Disease DIGESTIVE DISEASES AND SCIENCES Sharaf, R. N., Levesque, B. G., Shah, S., Longacre, T., Pasricha, P. J. 2011; 56 (1): 46-48

    View details for DOI 10.1007/s10620-010-1355-6

    View details for Web of Science ID 000286005900007

    View details for PubMedID 20668937

  • Probiotics for ulcerative colitis ... Are the good bugs back? Gastroenterology Shah, S. B. 2010; 139 (3): 1054-1056

    View details for DOI 10.1053/j.gastro.2010.07.032

    View details for PubMedID 20674868

  • Incidence and Risk of Intestinal and Extra-intestinal Complications in Medicaid Patients with Inflammatory Bowel Disease: A 5-Year Population-Based Study DIGESTIVE DISEASES AND SCIENCES Arora, G., Singh, G., Vadhavkar, S., Shah, S. B., Mannalithara, A., Mithal, A., Triadafilopoulos, G. 2010; 55 (6): 1689-1695


    Intestinal and extra-intestinal complications are associated with inflammatory bowel disease (IBD) but their exact incidence is not well known. In order to improve our understanding of their incidence and impact, we assessed the complications associated with ulcerative colitis (UC) and Crohn's disease (CD) in a population-based study in Medicaid patients.We utilized a retrospective cohort design and identified cases of UC and CD using Medi-Cal, the Medicaid program for the State of California. The disease cohort was age- and gender-matched to four controls each and the intestinal and extra-intestinal complications of CD and UC (analyzed separately) were studied over a period of 5 years following the initial diagnosis.For UC, the total number of intestinal complications, per 100 cases, was 92 observed compared to 21 expected; the total number of extra-intestinal complications was 42 observed compared to 30 expected. For CD, the number of intestinal complications was 81 observed compared to 20 expected and for extra-intestinal complications, 37 observed compared to 26 expected (all p < 0.001). For both UC and CD, bleeding was the most frequently seen intestinal complication, while the most common extra-intestinal complication was osteoporosis.IBD is associated with several intestinal and extra-intestinal complications of variable incidence and risk. Success of therapeutic regimens should be measured by decreases in incidence, risks, and costs of these complications, in addition to the usual impact on disease activity.

    View details for DOI 10.1007/s10620-010-1236-z

    View details for Web of Science ID 000278578800027

    View details for PubMedID 20428948

  • Atypical Rectal Bleeding: The Challenge of Diagnosing Mild Ulcerative Colitis DIGESTIVE DISEASES AND SCIENCES Levesque, B. G., Pai, R., Shah, S. B. 2010; 55 (3): 586-588

    View details for DOI 10.1007/s10620-010-1141-5

    View details for Web of Science ID 000274617500005

    View details for PubMedID 20140645

  • Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease REVIEWS IN GASTROENTEROLOGICAL DISORDERS Shah, S. B., Hanauer, S. B. 2008; 8 (3): 159-168


    With the introduction of biologic therapies for inflammatory bowel disease, significant questions have arisen regarding their best optimization. Although initial recommendations were to combine immunosuppressives with biologics to reduce immunogenicity, trials with 3 different anti-tumor necrosis factor agents (infliximab, adalimumab, and certolizumab) and a humanized monoclonal antibody that targets alpha-4 integrins (natalizumab) have failed to demonstrate the clinical superiority of combination therapy when high-dose induction and scheduled maintenance therapy was prescribed for up to 1 year. However, immunosuppressive agents should be considered with episodic biologic therapy to decrease immunogenicity and secondary loss of response. The issue of whether induction with biologics and maintenance therapy with immunosuppressives as monotherapy is as safe and effective as induction and maintenance with biologics alone still remains to be addressed. Further, with the use of concomitant immunosuppressives and biologics, evolving data raise concerns for an increase in adverse events, including opportunistic infections, neurological disorders, and cancer. Specific therapeutic decisions need to be individualized and the clinician must help the patient weigh quality-of-life issues with readiness to assume possible risks.

    View details for Web of Science ID 000259634300001

    View details for PubMedID 18957923

  • Intravenous cyclosporin in severe steroid-refractory ulcerative colitis: Long-term follow-up Oral presentation DDW 2008 Shah SB, Parekh NK, Hanauer SB, Cohen RD 2008; 134 (4)
  • Treatment of diarrhea in patients with inflammatory bowel disease: Concepts and cautions REVIEWS IN GASTROENTEROLOGICAL DISORDERS Shah, S. B., Hanauer, S. B. 2007; 7: S3-S10


    Diarrhea continues to be a prevalent symptom in patients with inflammatory bowel disease (IBD), requiring a wide differential diagnosis to define the pathophysiologic mechanisms in individual patients. It is essential that physicians properly evaluate complaints of diarrhea by assessing both patient symptoms and potential physiologic impacts on fluid and electrolyte status. Underlying mechanisms of diarrhea with IBD are the location, extent, and severity of inflammation; malabsorption; altered motility; and iatrogenic causes such as medications, diet, and antibiotic-associated colitis (eg, Clostridium difficile). When treating diarrhea, physicians need to control inflammatory activity using appropriate treatment algorithms. Therapies include aminosalicylates, corticosteroids, immune modifiers, and, most recently, biologic treatment. Other medications, including loperamide, diphenoxylate, codeine sulfate, and tinctures of opium, slow motility and increase the absorption of fluids and nutrients. For iatrogenic issues, medications that cause diarrhea should be withdrawn and individual diets modified. Not all diarrheas in the IBD patient are the same; therefore, it is essential to tailor therapies according to presumed etiologies. Antidiarrheal agents are not recommended in extremely ill patients and those with known hypersensitivity or evidence of obstruction or colonic dilation, fever, or abdominal tenderness. Concomitant use of loperamide with diphenoxylate and atropine should be avoided in early pregnancy.

    View details for Web of Science ID 000252144600002

    View details for PubMedID 18192964

  • Restoring a gastroenterology fellowship match: A trainee perspective AMERICAN JOURNAL OF GASTROENTEROLOGY Lim, J. K., Shah, S. B. 2004; 99 (8): 1412-1415

    View details for Web of Science ID 000223355200003

    View details for PubMedID 15307850

Stanford Medicine Resources: